{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:59:14Z","timestamp":1781643554028,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for patients with acute myeloid leukemia (AML) through an immune-mediated graft-versus-leukemia effect, but relapse is common. Studies in solid tumors have shown that adrenergic stress impairs anti-tumor immunity, and that beta-blockade can prolong survival in mice and patients receiving immunotherapy. To this end, we investigated whether beta-blocker use impacts outcomes in AML patients undergoing HSCT. We analyzed the cumulative incidences of relapse (CIR), non-relapse mortality (NRM) and overall survival (OS) in 413 patients with AML who underwent first allogeneic HSCT. A total of 112 patients (27%) received beta-blockers after HSCT. The use of beta-blockers was associated with a lower CIR (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.024), but with a higher NRM (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.002); OS did not differ. In multivariable analyses, beta-blocker use emerged as an independent factor associated with CIR (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.024) and NRM (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.012), but not OS (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.353). The occurrence of acute or chronic graft-versus-host disease (GvHD) was not significantly associated with beta-blocker use, but chronic GvHD or organ toxicity was more often the primary cause of death in the beta-blocker group (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.041). The use of angiotensin-converting enzyme (ACE) inhibitors\/angiotensin II receptor blockers (ARBs) or calcium channel blockers was not significantly associated with outcome. Our study is the first to demonstrate an association between beta-blocker use and post-transplant outcome in AML and supports further investigation of carefully titrated beta-adrenergic blockade as a potential means to influence donor cell immune responses in the transplant setting.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06962-w","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:58:09Z","timestamp":1774396689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia"],"prefix":"10.1007","volume":"105","author":[{"given":"Johanna","family":"Werk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Shaforostova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Reicherts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-5884","authenticated-orcid":false,"given":"Alexander","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"17","key":"6962_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMRA052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA (2006) Hematopoietic stem-cell transplantation. Engl N J Med 354(17):1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMRA052638","journal-title":"N Engl J Med"},{"issue":"5","key":"6962_CR2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole SW, Sood AK, Mar (2012) Molecular Pathways: Beta-Adrenergic Signaling in Cancer. Clin Cancer Res 18(5):1201\u20131206. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0641","journal-title":"Clin Cancer Res"},{"key":"6962_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3389\/fimmu.2018.00164","volume":"9","author":"G Qiao","year":"2018","unstructured":"Qiao G, Chen M, Bucsek MJ, Repasky A, Hylander S (2018) Adrenergic signaling: A targetable checkpoint limiting anti-tumor immunity and immunotherapy. Front Immunol 9:164. https:\/\/doi.org\/10.3389\/fimmu.2018.00164","journal-title":"Front Immunol"},{"issue":"11","key":"6962_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00262-014-1591-7","volume":"63","author":"JWL Eng","year":"2014","unstructured":"Eng JWL, Tannenbaum C, Pollak M (2014) A nervous tumor microenvironment: The impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response. Cancer Immunol Immunother 63(11):1115\u20131128. https:\/\/doi.org\/10.1007\/s00262-014-1591-7","journal-title":"Cancer Immunol Immunother"},{"key":"6962_CR5","doi-asserted-by":"crossref","unstructured":"Powe DG et al (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628\u2013638. Accessed: Oct. 14, 2025. [Online]. Available: https:\/\/www.impactjournals.com\/oncotarget\/www.impactjournals.com\/oncotarget628","DOI":"10.18632\/oncotarget.197"},{"key":"6962_CR6","doi-asserted-by":"publisher","unstructured":"Sharma E et al (2025) The impact of beta blockers on survival in cancer patients: a systematic review and meta-analysis. Cancers (Basel) 17(8). https:\/\/doi.org\/10.3390\/CANCERS17081357","DOI":"10.3390\/CANCERS17081357"},{"issue":"4","key":"6962_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H et al (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from hl-a-matched sibling donors1. Transplantation 18(4):295\u2013304. https:\/\/doi.org\/10.1097\/00007890-197410000-00001","journal-title":"Transplantation"},{"issue":"12","key":"6962_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"H Filipovich","year":"2005","unstructured":"Filipovich H et al (2005) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report, Biol. Blood Marrow Transpl 11(12):945\u2013956. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004","journal-title":"Blood Marrow Transpl"},{"issue":"3","key":"6962_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH et al (2015) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report, Biol. Blood Marrow Transpl 21(3):389\u2013401e1. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Blood Marrow Transpl"},{"issue":"1","key":"6962_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"C Harris","year":"2016","unstructured":"Harris C et al (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl 22(1):4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"6962_CR11","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","volume":"13","author":"E Copelan","year":"2007","unstructured":"Copelan E et al (2007) A scheme for defining cause of death and its application in the T cell depletion trial, Biol. Blood Marrow Transpl 13(12):1469\u20131476. https:\/\/doi.org\/10.1016\/j.bbmt.2007.08.047","journal-title":"Blood Marrow Transpl"},{"key":"6962_CR12","doi-asserted-by":"publisher","unstructured":"Kokolus KM et al (2018) Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology 7(3). https:\/\/doi.org\/10.1080\/2162402X.2017.1405205","DOI":"10.1080\/2162402X.2017.1405205"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06962-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06962-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06962-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:48:05Z","timestamp":1781642885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06962-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6962"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06962-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.L. received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. G.L. received honoraria not related to this study from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal\/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi.C.S. received honoraria for advisory boards from AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Laboratories Delbert, Jazz Pharmaceuticals, Novartis, Otsuka, Pfizer, and Roche. C.S. received institutional research support from Jazz Pharmaceuticals and travel or congress grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, and Pfizer.D. B. is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) \u2013 project number 413490537 within the Kiel Clinician Scientist Program in Evolutionary Medicine (CSEM).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of Westphalia-Lippe (reference number 2021-490-f-S) and was conducted in accordance with the Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived due to the retrospective nature of the study in accordance with the decision of the local ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"205"}}